These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 35733294)
1. Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease. Yoo H; Lee J; Kim B; Moon H; Jeong H; Lee K; Song WJ; Hur JK; Oh Y BMB Rep; 2022 Jul; 55(7):323-335. PubMed ID: 35733294 [TBL] [Abstract][Full Text] [Related]
2. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Oueslati A; Fournier M; Lashuel HA Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318 [TBL] [Abstract][Full Text] [Related]
3. Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson's Disease. He S; Wang F; Yung KKL; Zhang S; Qu S ACS Chem Neurosci; 2021 Apr; 12(7):1061-1071. PubMed ID: 33769791 [TBL] [Abstract][Full Text] [Related]
4. Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified α-Synuclein. Chen H; Zhao YF; Chen YX; Li YM ACS Chem Neurosci; 2019 Feb; 10(2):910-921. PubMed ID: 30628768 [TBL] [Abstract][Full Text] [Related]
5. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? Oueslati A J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784 [TBL] [Abstract][Full Text] [Related]
7. Targeting α-synuclein post-translational modifications in Parkinson's disease. Canever JB; Soares ES; de Avelar NCP; Cimarosti HI Behav Brain Res; 2023 Feb; 439():114204. PubMed ID: 36372243 [TBL] [Abstract][Full Text] [Related]
8. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors. Pajarillo E; Rizor A; Lee J; Aschner M; Lee E Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588 [TBL] [Abstract][Full Text] [Related]
9. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919 [TBL] [Abstract][Full Text] [Related]
10. Alpha synuclein post translational modifications: potential targets for Parkinson's disease therapy? Brembati V; Faustini G; Longhena F; Bellucci A Front Mol Neurosci; 2023; 16():1197853. PubMed ID: 37305556 [TBL] [Abstract][Full Text] [Related]
11. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy. Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358 [TBL] [Abstract][Full Text] [Related]
12. Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions. Gadhavi J; Patel M; Bhatia D; Gupta S Biochimie; 2022 Jan; 192():38-50. PubMed ID: 34582997 [TBL] [Abstract][Full Text] [Related]
13. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment. Kalsoom I; Wang Y; Li B; Wen H Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991 [TBL] [Abstract][Full Text] [Related]